Haverford Financial Services Inc. Purchases 4,433 Shares of Eli Lilly and Company $LLY

Haverford Financial Services Inc. raised its position in Eli Lilly and Company (NYSE:LLY) by 120.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,126 shares of the company’s stock after acquiring an additional 4,433 shares during the quarter. Eli Lilly and Company makes up about 1.9% of Haverford Financial Services Inc.’s investment portfolio, making the stock its 26th largest holding. Haverford Financial Services Inc.’s holdings in Eli Lilly and Company were worth $6,334,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the company. Braun Bostich & Associates Inc. grew its holdings in Eli Lilly and Company by 2.5% during the second quarter. Braun Bostich & Associates Inc. now owns 527 shares of the company’s stock worth $411,000 after purchasing an additional 13 shares during the period. Rise Advisors LLC raised its stake in Eli Lilly and Company by 1.8% in the second quarter. Rise Advisors LLC now owns 732 shares of the company’s stock valued at $571,000 after buying an additional 13 shares during the period. Occidental Asset Management LLC lifted its position in shares of Eli Lilly and Company by 0.7% in the second quarter. Occidental Asset Management LLC now owns 1,966 shares of the company’s stock valued at $1,533,000 after buying an additional 13 shares during the last quarter. New Insight Wealth Advisors boosted its stake in shares of Eli Lilly and Company by 3.4% during the 2nd quarter. New Insight Wealth Advisors now owns 394 shares of the company’s stock worth $307,000 after acquiring an additional 13 shares during the period. Finally, Dash Acquisitions Inc. increased its holdings in shares of Eli Lilly and Company by 2.8% during the 2nd quarter. Dash Acquisitions Inc. now owns 485 shares of the company’s stock worth $387,000 after acquiring an additional 13 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 0.9%

NYSE LLY opened at $1,030.49 on Wednesday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The company has a market cap of $974.21 billion, a price-to-earnings ratio of 67.35, a PEG ratio of 1.21 and a beta of 0.43. The company has a 50 day moving average of $838.20 and a 200-day moving average of $782.36. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,040.72.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter in the prior year, the business posted $1.18 earnings per share. The firm’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Wall Street Analysts Forecast Growth

Several research firms have commented on LLY. Guggenheim reiterated a “buy” rating and issued a $948.00 price objective on shares of Eli Lilly and Company in a report on Thursday, October 16th. DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, November 3rd. Daiwa Capital Markets lifted their price target on Eli Lilly and Company from $700.00 to $940.00 in a report on Monday, November 10th. Finally, Deutsche Bank Aktiengesellschaft decreased their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $1,020.37.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.